Therapeutic options for patients with inflammatory bowel disease: New steroids

Drugs of Today

Volumn 33, Issue 2, 1997, Pages 131-138

  Brynskov, Jørn ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; HYDROCORTISONE; MESALAZINE; PREDNISOLONE;

ARTICLE; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; HUMAN; RECTAL DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION; TOPICAL DRUG ADMINISTRATION;

EID: 0030988796     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Hodgson, H.F.J. One disease or two?In: Inflammatory Bowel Diseases, 2nd Edition. Allan, R.N., Keighley, M.R.B., Alexander-Williams, J., Hawkins, C.F., (Eds.). Churchill Livingstone: London 1990, 121-6.
2. Brynskov, J., Nielsen, O.H., Ahnefeldt-Rønne, I., Bendtzen, K. Review: Cytokines in inflammatory bowel disease. Scand J Gastroenterol 1992, 27: 897-906.
3. Brynskov, J., Nielsen, O.H., Ahnfeldt-Rønne, I., Bendtzen, K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): A review. Dig Dis 1994, 12: 290-304.
4. Brynskov, J. Cyclosporin in Crohn's disease. Therapeutic andpathogenetic implications. Dan Med Bull 1994, 41: 332-44.
5. Brynskov, J., Nørby Rasmussen, S. Clinical pharmacology in gastroenterology. Development of new forms of treatment of inflammatory bowel disease. Scand J Gastroenterol 1995, 31(Suppl. 216): 175-80.
6. Jewell, D.P. Corticosteroids for the management of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1989, 18: 21-34.
7. Brattsand, R.L. Steroid development: A case of enhanced selectivity for the bowel wall. Res Clin Forum 1993, 15: 17-31.
8. Brattsand, R.L. Concepts of topical steroid therapy. Res Clin Forum 1996, 18: 56-65.
9. Brattsand, R.L., Linden, M. Cytokinemodulation by glucocorticoids: Mechanisms and actions in cellular studies. Aliment Pharmacol Ther 1996, 10(Suppl. 2): 81-90.
10. Marx, J. How the glucocorticoids suppress immunity. Science 1995, 270: 232-3.
11. Scheinman, R.I., Cogswell, P.C., Lofquist, A.K., Baldwin, A.S. Role of transcriptional activation of INβα in mediation of immunosuppression by glucocorticoids. Science 1995, 270: 283-6.
12. Auphan, N., DiDonato, J.A., Rosette, C., Helmberg, A., Karin, M. Immunosuppression of glucocorticoids: Inhibition of NF-Nβ activity through induction of INβ synthesis. Science 1995, 270: 286-90.
13. Pedersen, G., Brynskov, J., Nielsen, O.H., Bendtzen, K. Adhesion molecules in inflammatory and neoplastic intestinal diseases. Dig Dis 1995, 13: 322-36.
14. Nielsen, O.H., Langholtz, E., Hendel, J., Brynskov, J. Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease. Dig Dis Sci 1994, 39: 1918-23.
15. Nielsen, O.H., Brynskov, J., Vainer, B. Increased mucosal concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin, and interleukin-8 in active ulcerative colitis. Dig Dis Sci 1996, 41: 1780-5.
16. Bailey, C.J., Hembry, R.M., Alexander, A., Irving, M.H., Grant, M.E., Shuttleworth, C.A. Distribution of the matrix metalloproteinases stromelysin, gelatinase A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol 1994, 47: 113-6.
17. 4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986, 91: 837-44.
18. Thomsen, Ø.O., Andersen, T., Langholz, E. et al. Lack of adrenal gland suppression with budesonide enema in active ulcerative colitis: A prednisolone-controlled 8-week study. Eur J Gastroenterol Hepatol 1994, 6: 507-11.
19. Thomsen, Ø.O. Safety overview of budesonide in inflammatory bowel diseases. Res Clin Forum 1996, 18: 91-100.
20. Hanauer, S.B., Kirsner, J.B., Barrett, W.E. The treatment of left-sided ulcerative colitis with tixocortol pivalate. Gastroenterology 1986, 90(Suppl.): 1449A.
21. Angus, P., Snook, J.A., Reid, M., Jewell, D.P. Oral fluticasone propionate in active ulcerative colitis. Gut 1992, 33: 711-4.
22. Wright, J.P., Jarnum, S., Schaffalitzky de Muckadell, O.B., Keech, M.L., Lennard-Jones, J.E. Oral fluticasone propionate compared with prednisolone in treatment of active Crohn's disease: A randomized double-blind multicentre study. Eur J Gastroenterol Hepatol 1993, 5: 499-503.
23. Danielsson, A. Review: Treatment of distal ulcerative colitis with nonsystemic corticosteroid enemas. Scand J Gastroenterol 1996, 31: 945-53.
24. Matts, S.G.F., Gaskell, K.H. Retrograde colonic spread of enemata in ulcerative colitis. Br Med J 1961, 2: 614-7.
25. Truelove, S.C. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium. Br Med J 1968, 2: 1072-6.
26. Watkinson, G. Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate sodium. Br Med J 1958, 2: 1077-82.
27. A Multicentre Trial. Betamethasone 17-valerate and prednisolone 21-phosphate retention enemata in proctitis. Br Med J 1971, 3: 84-6.
28. Mulder, C.J.J., Endert, E., Van der Heide, H. et al. Comparison of beclomethasone dipropionate (2 and 3 mg) and prednisolone sodium phosphate enemas (30 mg) in the treatment of ulcerative colitis. Neth J Med 1989, 35: 18-24.
29. Ruddel, W.S.J., Dickinson, R.J., Dixon, M.F., Axon, A.T.R. Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: Comparison of hydrocortisone enemas and rectal hydrocortisone foam. Gut 1980, 21: 885-9.
30. The Danish Budesonide Study Group. Budesonide enema in distal ulcerative colitis. A randomized dose-response trial with prednisolone enema as positive control. Scand J Gastroenterol 1991, 26: 1225-30.
31. Hanauer, S.B., Robinson, M. for the U.S. Budesonide Enema Study Group. Dose ranging study of budesonide enema in active distal ulcerative colitis. Gastroenterology 1995, 108: A833.
32. Danielsson, Å., Löfberg, R., Persson, T. et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 1992, 27: 9-12.
33. Bayless, T., Sninsky, C. for the U.S. Budesonide Enema Study Group. Budesonide enema is an effective alternative to hydrocortisone enema in active distal ulcerative colitis. Gastroenterology 1995, 108: A778.
34. Danielsson, Å., Hellers, G., Lyrenäs, E., Löfberg, R., Nilsson, Å., Olsson, O. A controlled randomised trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987, 22: 987-92.
35. Bianchi-Porro, G., Prantera, C., Campieri, M. et al. Comparative trial of methylprednisolone and budesonide enemas in active distal ulcerative colitis. Eur J Gastroenterol Hepatol 1994, 6: 125-30.
36. Löfberg, R., Thomsen, Ø.O., Langholz, E. et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther 1994, 8: 623-9.
37. Lamers, C., Meijer, J., Engels, L. et al. Comparative study of the topically acting glucocorticosteroid budesonide and 5-aminosalicylic acid enema therapy of proctitis and proctosigmoiditis. Gastroenterology 1991, 100: A233.
38. Lemann, M., Rutgeerts, P., Van Heuverzwijn, R. et al. Comparison of budesonide enema and 5-ASA enema in the treatment of active distal ulcerative colitis. Hell J Gastroenterol 1992, 5 (Suppl.): 194.
39. Järnerot, G., Lennard-Jones, J., Bianchi-Porro, G., Brynskov, J., Campieri, M., Present, D. International Working Team Report: Medical treatment of refractory distal ulcerative colitis. Gastroenterol Int 1991, 4: 93-8.
40. Summers, R.W., Switz, D.M., Sessions, J.T. et al.National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1979, 77: 847-69.
41. Malchow, H., Ewe, K., Brandes, J.W. et al. European Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1984, 86: 249-66.
42. Munkholm, P., Langholz, E., Davidsen, M., Binder, V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1993, 35: 360-2.
43. Edsbäcker, S., Wollmer, P., Nilsson, Å., Nilsson, M. Pharmacokinetics and gastrointestinal transit of budesonide controlled ileal release (CIR) capsules. Gastroenterology 1993, 104 (Suppl.): A695.
44. Löfberg, R., Danielsson, Å., Salde, L. Oral budesonide in active Crohn's disease. Aliment Pharmacol Ther 1993, 7: 611-6.6.
45. Greenberg, G.R., Feagan, B.G., Martin, F. et al. Oral budesonide for active Crohn's disease. New Engl J Med 1994, 331: 836-41.
46. Rutgeerts, P., Löfberg, R., Malchow, H. et al. A comparison of budesonide with prednisolone for active Crohn's disease. New Engl J Med 1994, 331: 842-5.
47. Greenberg, G.R., Feagan, B.G., Martin, F. et al. Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. Gastroenterology 1996, 110: 45-51.
48. Löfberg, R., Rutgeerts, P., Malchow, H. et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. Gut 1996, 39: 82-6.
49. Järneroth, G., Rolny, P., Sandberg-Gertzen, H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985, 89: 1005-113.
50. Löfberg, R., Danielsson, Å., Suhr, O. et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996, 110: 1712-8.
51. Langholz, E., Munkholm, P., Davidsen, M., Binder, V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992, 103: 1444-51.